Word

SIMCERE

Status

Registered

Status Code

700

Status Date

Tuesday, November 24, 2020

Serial Number

79276391

Registration Number

6202775

Registration Date

Tuesday, November 24, 2020

Mark Type

3000

Filing Date

Monday, September 2, 2019

Published for Opposition

Tuesday, September 8, 2020

Trademark Owner History

Jiangsu Simcere Pharmaceutical Co., Ltd - Original Registrant

Classifications

5 Medicated troches; Medicines for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes; [ Biochemicial ] * Biochemical * drug for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musculo-skeletal disorders, infections, and bacterial infections, all for human purposes; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical purposes; Active pharmaceutical ingredients, namely, extracts of hops for pharmaceutical purposes, eucalyptus for pharmaceutical purposes, mint for pharmaceutical purposes, malt for pharmaceutical purposes, pepsins for pharmaceutical purposes,thymol for pharmaceutical purposes,turpentine for pharmaceutical purposes, flaxseed for pharmaceutical purposes, ferments for pharmaceutical purposes, cytostatics for pharmaceutical purposes, balms for pharmaceutical purposes, digestives for pharmaceutical purposes, iodine for pharmaceutical purposes, alcohol for pharmaceutical purposes, starch for pharmaceutical purposes; Pharmaceutical preparations for injection for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes; Chinese patent medicines for the prevention and treatment of cancer, central nervous system diseases, autoimmune diseases, cardiovascular diseases, gastrointestinal diseases, lung disease, osteoporosis, rickets, chondropathy, renal osteopathy, hypoparathyroidism, dental diseases, hyperlipidemia, depression, hypercholesteremia, kidney diseases, and, musclo-skeletal disorders, infections, and bacterial infections, all for human purposes

The mark consists of a design of a running person composed of geometric figures, displayed within a flag-like rectangular design and the wording "SIMCERE" to the right.
In the statement, " International Class 5 " is corrected per the restriction notice dated 7/6/2023
Color is not claimed as a feature of the mark.

Trademark Events

Apr 8, 2024

Partial Invalidation Of Reg Ext Protection Created

Sep 12, 2023

Notice Of Updated Registration Confirmation Emailed

Aug 16, 2023

Correction From Ib Entered - No Review Required

Aug 8, 2023

Case Assigned To Post Registration Paralegal

Aug 8, 2023

Correction Under Section 7 - Processed

Aug 8, 2023

Case Assigned To Post Registration Paralegal

Jul 9, 2023

Correction Transaction Received From Ib

Oct 27, 2021

New Representative At Ib Received

Mar 21, 2021

Final Decision Transaction Processed By Ib

Feb 26, 2021

Final Disposition Notice Sent To Ib

Feb 26, 2021

Final Disposition Processed

Feb 24, 2021

Final Disposition Notice Created, To Be Sent To Ib

Nov 24, 2020

Registered-Principal Register

Sep 8, 2020

Official Gazette Publication Confirmation E-Mailed

Sep 8, 2020

Published For Opposition

Aug 19, 2020

Notification Of Notice Of Publication E-Mailed

Aug 3, 2020

Approved For Pub - Principal Register

Aug 3, 2020

Examiner's Amendment Entered

Aug 3, 2020

Notification Of Examiners Amendment E-Mailed

Aug 3, 2020

Examiners Amendment E-Mailed

Aug 3, 2020

Examiners Amendment -Written

Jul 27, 2020

Applicant/Correspondence Changes (Non-Responsive) Entered

Jul 27, 2020

Teas Change Of Correspondence Received

Jul 27, 2020

Teas Change Of Owner Address Received

Jul 24, 2020

Teas/Email Correspondence Entered

Jul 23, 2020

Correspondence Received In Law Office

Jul 23, 2020

Teas Response To Office Action Received

Mar 13, 2020

Refusal Processed By Ib

Feb 22, 2020

Non-Final Action Mailed - Refusal Sent To Ib

Feb 22, 2020

Refusal Processed By Mpu

Jan 28, 2020

Non-Final Action (Ib Refusal) Prepared For Review

Jan 27, 2020

Non-Final Action Written

Jan 21, 2020

Application Filing Receipt Mailed

Jan 17, 2020

Assigned To Examiner

Jan 17, 2020

New Application Office Supplied Data Entered

Jan 16, 2020

Sn Assigned For Sect 66a Appl From Ib